Get more information on Macro & Micro Economic Factor Analysis, Statistical Tools, and Trend Projection at Affordable Pricing options. Learn More
The Biologic Therapy Market value is set to grow by USD 226.61 billion, progressing at a CAGR of 11% from 2020 to 2025, as per the latest report by Technavio. Moreover, the market is segmented by product (antibody therapeutics, vaccines, cell therapy, gene therapy, and other therapies) and geography (North America, Europe, Asia, and ROW).
Biologic Therapy Market 2021-2025: Segmentation
- Product
- Antibody Therapeutics
- Vaccines
- Cell Therapy
- Gene Therapy
- Other Therapies
The biologic therapy market share growth by antibody therapeutics will be significant during the forecast period. Monoclonal antibodies are amongst the most widely sold biologics and are even referred to as the future of medicine. Monoclonal antibodies are cloned from single-parent cells and are designed to recognize and bind to specific receptors on the surface of the cells. This specificity in action makes monoclonal antibodies more effective than conventional treatments for immunological and chronic ailments like cancer. Owing to these factors, it is expected that the global biologic therapy market will grow during the forecast period.
- Geography
- North America
- Europe
- Asia
- ROW
57% of the market's growth will originate from North America during the forecast period. The US is the key market for biologic therapy in North America. Market growth in this region will be slower than the growth of the market in the Asia region. One of the reasons for market growth in the Americas is the increased incidence of chronic diseases. The rise in the prevalence of major health disorders is mainly due to lifestyle changes and increased consumption of alcohol and tobacco in the US. However, market growth is expected to be only gradual due to the patent expiry of major biologics present in the market.
Biologic Therapy Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 11% |
Market growth 2021-2025 |
$ 226.61 billion |
Market structure |
Concentrated |
YoY growth (%) |
9.71 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 57% |
Key consumer countries |
US, Japan, Germany, France, and UK |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization preview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Biologic Therapy Market 2021-2025: Scope
High cost of biologics is one of the key challenges hindering the biologic therapy market growth. Biologics can be used for the treatment of several types of malignancies, hormonal imbalances, and autoimmune conditions, but they are expensive, which makes them beyond the reach of the economically underprivileged. The total manufacturing costs, which include the costs related to the clinical trials associated with biologics, account for vendors offering these products at high costs. The development of a biological molecule requires a separate living organism. Though bacterial production is not that costly, the production of therapeutic agents like monoclonal antibodies and vaccines becomes costly as they involve animal handling. The immunization of the animal and other procedures related to the production of antibodies and vaccines increases the cost of that product. Due to the high price of biologic therapy, many patients are unable to access this effective therapy, and this will remain a major challenge for the market during the forecast period.
Biologic Therapy Market 2021-2025: Vendor Analysis
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- AbbVie Inc.
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
The biologic therapy market is concentrated and the vendors are deploying growth strategies such as partnering with research organizations and hospitals for R&D to compete in the market.
Biologic Therapy Market 2021-2025: Key Highlights
- CAGR of the market during the forecast period 2021-2025
- Detailed information on factors that will assist biologic therapy market growth during the next five years
- Estimation of the biologic therapy market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the biologic therapy market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of biologic therapy market vendors
Related Reports:
Head and Neck Cancer Diagnostics Market by Diagnostic Methods and Geography - Forecast and Analysis 2020-2024: The head and neck cancer diagnostics market size has the potential to grow by USD 3.41 billion during 2020-2024. The market's growth momentum will accelerate throughout the forecast period. Latest Exclusive Research Insights Here
Global Spine Biologics Market 2018-2022: The global spine biologics market size will grow by USD 418.72 million during 2018-2022. This industry research report provides a detailed analysis of the market based on product (bone grafts, BMP, BMAC, and others) and geography (the Americas, APAC, and EMEA). Latest Exclusive Research Insights Here
Table of Contents:
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- Exhibit 02: Market characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 03: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 04: Market segments
- 3.4 Market outlook: Forecast for 2020 - 2025
- Exhibit 05: Global - Market size and forecast 2020 - 2025 ($ billion)
- Exhibit 06: Global market: Year-over-year growth 2020 - 2025 (%)
- 3.5 Market by application
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 07: Five forces analysis 2020 & 2025
- 4.2 Bargaining power of buyers
- Exhibit 08: Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- Exhibit 09: Bargaining power of suppliers
- 4.4 Threat of new entrants
- Exhibit 10: Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 11: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 12: Threat of rivalry
- 4.7 Market condition
- Exhibit 13: Market condition - Five forces 2020
5 Market Segmentation by Product
- 5.1 Market segments
- Exhibit 14: Product - Market share 2020-2025 (%)
- 5.2 Comparison by Product
- Exhibit 15: Comparison by Product
- 5.3 Antibody therapeutics - Market size and forecast 2020-2025
- Exhibit 16: Antibody therapeutics - Market size and forecast 2020-2025 ($ billion)
- Exhibit 17: Sales of major monoclonal antibodies 2018-2020 ($ million)
- Exhibit 18: Antibody therapeutics - Year-over-year growth 2020-2025 (%)
- 5.4 Vaccines - Market size and forecast 2020-2025
- Exhibit 19: Vaccines - Market size and forecast 2020-2025 ($ billion)
- Exhibit 20: Vendors offering vaccines
- Exhibit 21: Vaccines - Year-over-year growth 2020-2025 (%)
- 5.5 Cell therapy - Market size and forecast 2020-2025
- Exhibit 22: Cell therapy - Market size and forecast 2020-2025 ($ billion)
- Exhibit 23: Cell therapy - Year-over-year growth 2020-2025 (%)
- 5.6 Gene therapy - Market size and forecast 2020-2025
- Exhibit 24: Gene therapy - Market size and forecast 2020-2025 ($ billion)
- Exhibit 25: Gene therapy - Year-over-year growth 2020-2025 (%)
- 5.7 Other therapies - Market size and forecast 2020-2025
- Exhibit 26: Other therapies - Market size and forecast 2020-2025 ($ billion)
- Exhibit 27: Other therapies - Year-over-year growth 2020-2025 (%)
- 5.8 Market opportunity by Product
- Exhibit 28: Market opportunity by Product
6 Customer landscape
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 30: Market share by geography 2020-2025 (%)
- 7.2 Geographic comparison
- Exhibit 31: Geographic comparison
- 7.3 North America - Market size and forecast 2020-2025
- Exhibit 32: North America - Market size and forecast 2020-2025 ($ billion)
- Exhibit 33: North America - Year-over-year growth 2020-2025 (%)
- 7.4 Europe - Market size and forecast 2020-2025
- Exhibit 34: Europe - Market size and forecast 2020-2025 ($ billion)
- Exhibit 35: Europe - Year-over-year growth 2020-2025 (%)
- 7.5 Asia - Market size and forecast 2020-2025
- Exhibit 36: Asia - Market size and forecast 2020-2025 ($ billion)
- Exhibit 37: Asia - Year-over-year growth 2020-2025 (%)
- 7.6 ROW - Market size and forecast 2020-2025
- Exhibit 38: ROW - Market size and forecast 2020-2025 ($ billion)
- Exhibit 39: ROW - Year-over-year growth 2020-2025 (%)
- 7.7 Key leading countries
- Exhibit 40: Key leading countries
- 7.8 Market opportunity by geography
- Exhibit 41: Market opportunity by geography ($ billion)
8 Drivers, Challenges, and Trends
- 8.2 Market challenges
- Exhibit 43: Impact of drivers and challenges
9 Vendor Landscape
- 9.1 Overview
- Exhibit 44: Vendor landscape
- 9.2 Landscape disruption
- Exhibit 45: Landscape disruption
- Exhibit 46: Industry risks
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 47: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 48: Market positioning of vendors
- 10.3 AbbVie Inc.
- Exhibit 49: AbbVie Inc. - Overview
- Exhibit 50: AbbVie Inc. - Product and service
- Exhibit 51: AbbVie Inc. – Key news
- Exhibit 52: AbbVie Inc. - Key offerings
- 10.4 AstraZeneca Plc
- Exhibit 53: AstraZeneca Plc - Overview
- Exhibit 54: AstraZeneca Plc - Product and service
- Exhibit 55: AstraZeneca Plc – Key news
- Exhibit 56: AstraZeneca Plc - Key offerings
- 10.5 Bristol-Myers Squibb Co.
- Exhibit 57: Bristol-Myers Squibb Co. - Overview
- Exhibit 58: Bristol-Myers Squibb Co. - Product and service
- Exhibit 59: Bristol-Myers Squibb Co. – Key news
- Exhibit 60: Bristol-Myers Squibb Co. - Key offerings
- 10.6 F. Hoffmann-La Roche Ltd.
- Exhibit 61: F. Hoffmann-La Roche Ltd. - Overview
- Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
- Exhibit 63: F. Hoffmann-La Roche Ltd. – Key news
- Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings
- Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus
- 10.7 GlaxoSmithKline Plc
- Exhibit 66: GlaxoSmithKline Plc - Overview
- Exhibit 67: GlaxoSmithKline Plc - Business segments
- Exhibit 68: GlaxoSmithKline Plc – Key news
- Exhibit 69: GlaxoSmithKline Plc - Key offerings
- Exhibit 70: GlaxoSmithKline Plc - Segment focus
- 10.8 Johnson and Johnson Inc.
- Exhibit 71: Johnson and Johnson Inc. - Overview
- Exhibit 72: Johnson and Johnson Inc. - Business segments
- Exhibit 73: Johnson and Johnson Inc. – Key news
- Exhibit 74: Johnson and Johnson Inc. - Key offerings
- Exhibit 75: Johnson and Johnson Inc. - Segment focus
- 10.9 Merck and Co. Inc.
- Exhibit 76: Merck and Co. Inc. - Overview
- Exhibit 77: Merck and Co. Inc. - Business segments
- Exhibit 78: Merck and Co. Inc. – Key news
- Exhibit 79: Merck and Co. Inc. - Key offerings
- Exhibit 80: Merck and Co. Inc. - Segment focus
- 10.10 Novartis AG
- Exhibit 81: Novartis AG - Overview
- Exhibit 82: Novartis AG - Business segments
- Exhibit 83: Novartis AG – Key news
- Exhibit 84: Novartis AG - Key offerings
- Exhibit 85: Novartis AG - Segment focus
- 10.11 Pfizer Inc.
- Exhibit 86: Pfizer Inc. - Overview
- Exhibit 87: Pfizer Inc. - Business segments
- Exhibit 88: Pfizer Inc. – Key news
- Exhibit 89: Pfizer Inc. - Key offerings
- 10.12 Sanofi SA
- Exhibit 90: Sanofi SA - Overview
- Exhibit 91: Sanofi SA - Business segments
- Exhibit 92: Sanofi SA – Key news
- Exhibit 93: Sanofi SA - Key offerings
- Exhibit 94: Sanofi SA - Segment focus
11 Appendix
- 11.2 Currency conversion rates for US$
- Exhibit 95: Currency conversion rates for US$
- 11.3 Research methodology
- Exhibit 96: Research Methodology
- Exhibit 97: Validation techniques employed for market sizing
- Exhibit 98: Information sources
- 11.4 List of abbreviations
- Exhibit 99: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article